Patents by Inventor Peter Valent
Peter Valent has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20090148466Abstract: A process for the preparation of an hypoallergenic mosaic antigen derived from an allergen is disclosed whereby a) in a first step the allergen is split into at least two parts and the IgE reactivity of each part is determined and b) in a second step those parts of the allergen which have no detectable IgE reaction are combined to a mosaic antigen which comprises the amino acids of the allergen but the order of the amino acids of the mosaic antigen is different from that of the naturally occurring allergen.Type: ApplicationFiled: January 7, 2009Publication date: June 11, 2009Applicant: BIOMAY AGInventors: Nadine MOTHES, Sabine Stumvoll, Margit Focke, Birgit Linhart, Maria-Theresa Krauth, Peter Valent, Dietrich Kraft, Rudolf Valenta
-
Publication number: 20090104208Abstract: A polypeptide comprising an amino acid sequence having at least 60% identity to the amino acid sequence SEQ ID No. 1 or comprising at least one amino acid fragment of at least 6 consecutive amino acid residues of the amino acid sequence SEQ ID No. 1 or having immunological cross-reactivity to the amino acid sequence SEQ ID No. 1 or fragments thereof, wherein the amino acid sequence SEQ ID No. 1 codes for an allergen and the polypeptide comprises at least one T cell epitope recognized by a T cell receptor specific for a molecule having the amino acid sequence SEQ ID No. 1.Type: ApplicationFiled: April 27, 2007Publication date: April 23, 2009Applicant: BIOMAY AGInventors: Rudolf Valenta, Margit Weghofer, Susanne Vrtala, Friedrich Horak, Peter Valent, Stefan Florian
-
Publication number: 20090098167Abstract: Method for producing derivatives of wild-type protein allergen Phl p 1 with reduced allergenic activity compared to the wild-type allergen, comprising the following steps: providing wild-type protein allergen Phl p 1, fragmenting said wild-type protein allergen into at least three fragments, wherein at least one fragment of said at least three fragments comprises at least one T-cell epitope and said at least three fragments have a reduced allergenic activity or lack allergenic activity and rejoining said at least three fragments in an order differing from the order of the fragments in the wild-type allergen.Type: ApplicationFiled: May 3, 2007Publication date: April 16, 2009Applicants: BIOMAY AG, ALLERGOPHARMA JOACHIM GANZER KGInventors: Tanja Ball, Birgit Linhart, Peter Valent, Angelika Stocklinger, Christian Lupinek, Josef Thalhamer, Rudolf Valenta
-
Publication number: 20090074801Abstract: The present invention pertains to polypeptides derived from the timothy grass pollen allergen Phl p 7. The polypeptides display reduced allergen activity and are useful as allergy vaccines for the treatment of sensitized allergic patients and for prophylactic vaccination.Type: ApplicationFiled: August 11, 2008Publication date: March 19, 2009Applicant: BIOMAY Produktions-und Handels-AktiengesellschaftInventors: Kerstin WESTRITSCHNIG, Margarete Focke, Anna Twardosz, Peter Valent, Petra Verdino, Walter Keller, Dietrich Kraft, Rudolf Valenta
-
Patent number: 7491396Abstract: A process for the preparation of an hypoallergenic mosaic antigen derived from an allergen is disclosed whereby a) in a first step the allergen is split into at least two parts and the IgE reactivity of each part is determined and b) in a second step those parts of the allergen which have no detectable IgE reaction are combined to a mosaic antigen which comprises the amino acids of the allergen but the order of the amino acids of the mosaic antigen is different from that of the naturally occurring allergen.Type: GrantFiled: December 18, 2003Date of Patent: February 17, 2009Assignee: Biomay AGInventors: Nadine Mothes, Sabine Stumvoll, Margit Focke, Birgit Linhart, Maria-Theresa Krauth, Peter Valent, Dietrich Kraft, Rudolf Valenta
-
Patent number: 7485305Abstract: The present invention relates to a novel allergen from house-dust mites, to polypeptides derived from said allergen and polynucleotides encoding the same. Furthermore, the invention provides antibodies directed against the allergen and to the use of the polypeptides, polynucleotides and/or antibodies in therapy and diagnosis of allergic disorders.Type: GrantFiled: June 1, 2005Date of Patent: February 3, 2009Assignee: Biomay AGInventors: Rudolf Valenta, Peter Valent, Margit Weghofer, Susanne Vrtala, Maria-Theresia Krauth
-
Patent number: 7482010Abstract: The invention relates to a hypoallergenic immunogenic molecule derived from the Phl p 6 allergen, wherein the Phl p 6 molecule has an N-terminal and/or C-terminal deletion which makes the molecule at least substantially lack IgE binding capacity. The invention also relates to a hypoallergenic immunogenic combination of molecules derived from the Phl p 6 allergen, comprising (i) a Phl p 6 molecule having an N-terminal deletion which makes the molecule at least substantially lack IgE binding capacity, and (ii) a Phl p 6 molecule having a C-terminal deletion which makes the molecule at least substantially lack IgE binding capacity, which two molecules together encompass the complete sequence of Phl p 6. The invention further relates to the use of the hypoallergenic immunogenic molecule or molecule mixture in hyposensitization and diagnosis.Type: GrantFiled: November 27, 2002Date of Patent: January 27, 2009Assignee: Phadia ABInventors: Rudolf Valenta, Susanne Vrtala, Sabine Stummfoll, Hans Grönlund, Monika Grote, Luca Vangelista, Annalisa Pastore, Wolfgang R. Sperr, Peter Valent, Dietrich Kraft
-
Patent number: 7482009Abstract: The invention relates to a hypoallergenic immunogenic molecule derived from the Phl p 6 allergen, wherein the Phl p6 molecule has an N-terminal and/or C-terminal deletion which makes the molecule at least substantially lack IgE binding capacity. The invention also relates to a hypoallergenic immunogenic combination of molecules derived from the Phl p 6 allergen, comprising (i) a Phl p 6 molecule having an N-terminal deletion which makes the molecule at least substantially lack IgE binding capacity, and (ii) a Phl p 6 molecule having a C-terminal deletion which makes the molecule at least substantially lack IgE binding capacity, which two molecules together encompass the complete sequence of Phl p 6. The invention further relates to the use of the hypoallergenic immunogenic molecule or molecule mixture in hyposensitization and diagnosis.Type: GrantFiled: May 10, 2002Date of Patent: January 27, 2009Assignee: Phadia ABInventors: Rudolf Valenta, Susanne Vrtala, Sabine Stummfoll, Hans Grönlund, Monika Grote, Luca Vangelista, Annalisa Pastore, Wolfgang R. Sperr, Peter Valent, Dietrich Kraft
-
Publication number: 20090017051Abstract: The present invention relates to a pharmaceutical composition containing a peptide and a pharmaceutically acceptable carrier or diluent wherein the peptide has a length of 8 to 50 amino acids, at least three preferably consecutive amino acids of the peptide are identical to at least three amino acids which appear in close vicinity on the molecular surface of an allergenic protein, and said at least three amino acids are solvent-exposed amino acids in the allergenic protein. The invention also concerns a method for the preparation of the pharmaceutical composition.Type: ApplicationFiled: February 28, 2007Publication date: January 15, 2009Inventors: Margarete Focke, Vera Mahler, Wolfgang R. Sperr, Peter Valent, Dietrich Kraft, Rudolf Valenta
-
Publication number: 20080286311Abstract: The present invention relates to a method for producing derivatives of wild-type protein allergens with reduced allergenic activity, characterized in by the following steps: providing a wild-type protein allergen with an allergenic activity, splicing said wild-type protein allergen into two parts, said two parts having a reduced allergenic activity or lacking allergenic activity and rejoining said two fragments in inverse orientation; as well as allergen derivatives.Type: ApplicationFiled: December 2, 2005Publication date: November 20, 2008Applicant: BIOMAY AGInventors: Kerstin Westritschnig, Margarete Focke, Peter Valent, Walter Keller, Rudolf Valenta
-
Publication number: 20080261215Abstract: The present invention discloses a method for evaluating the allergen sensitivity of an individual and/or the clinical efficacy of an allergen immunotherapy comprising the steps: providing at least two samples selected from the group consisting of blood or fractions thereof, connective tissue, nasal, bronchial, skin or gut biopsy material from an individual subjected or intended to be subjected to an immunotherapy with at least one pure allergen or derivative thereof, wherein the samples contain cells capable of releasing mediators in response to said allergen, contacting said sample with said allergen or derivative thereof, and determining the amounts of mediators released from said sample and evaluating the allergen sensitivity of the individual prior to therapy and/or the clinical efficacy of the immunotherapy by comparing said amounts.Type: ApplicationFiled: February 9, 2006Publication date: October 23, 2008Applicant: BIOMAY AGInventors: Ashok Purohit, Carine Metz-Favre, Sylvia Laffer, Rudolf Valenta, Nadine Mothes-Luksch, Peter Valent, Angele Verot, Gabrielle Pauli
-
Patent number: 7425333Abstract: The present invention pertains to polypeptides derived from the timothy grass pollen allergen Phl p 7. The polypeptides display reduced allergen activity and are useful as allergy vaccines for treatment of sensitized allergic patients and for prophylactic vaccination.Type: GrantFiled: September 25, 2003Date of Patent: September 16, 2008Assignee: Biomay Produktions-und Handels-AktiengesellschaftInventors: Kerstin Westritschnig, Margarete Focke, Anna Twardosz, Peter Valent, Petra Verdino, Walter Keller, Dietrich Kraft, Rudolf Valenta
-
Publication number: 20080160038Abstract: Methods for desensitization of a mammal suffering from IgE mediated allergy comprise the steps of: administering to said mammal a therapeutically effective amount of an immunogenic and hypoallergenic composition which comprises (i) a Phi p 6 molecule having an N-terminal truncation which makes the molecule at least lack IgE binding capacity, and/or (ii) a Phi p 6 molecule having a C-terminal truncation which makes the molecule at least lack IgE binding capacity, wherein the molecules of (i) and (ii), if employed in combination, together span the complete sequence of Phl p 6, and a pharmaceutically acceptable carrier.Type: ApplicationFiled: November 1, 2007Publication date: July 3, 2008Inventors: Rudolf Valenta, Susanne Vrtala, Sabine Stumvoll, Hans Gronlund, Monika Grote, Luca Vangelista, Annalisa Pastore, Wolfgang R. Sperr, Peter Valent, Dietrich Kraft
-
Patent number: 7279295Abstract: The present invention relates to a novel allergen from timothy grass (Phleum pretense) pollen, Phl p11 as disclosed in SEQ ID NO:2, and use thereof as a reagent and in a diagnositic kit as well as for immunotherapy.Type: GrantFiled: March 27, 2003Date of Patent: October 9, 2007Assignee: Phadia ABInventors: Asa Marknell Dewitt, Verena Niederberger, Pirjo Lehtonen, Susanne Spitzauer, Wolfgang R. Sperr, Peter Valent, Rudolf Valenta, Jonas Lidholm
-
Patent number: 7244431Abstract: The present invention relates to a pharmaceutical composition containing a peptide and a pharmaceutically acceptable carrier or diluent wherein the peptide has a length of 8 to 50 amino acids, at least three preferably consecutive amino acids of the peptide are identical to at least three amino acids which appear in close vicinity on the molecular surface of an allergenic protein, and said at least three amino acids are solvent-exposed amino acids in the allergenic protein. The invention also concerns a method for the preparation of the pharmaceutical composition.Type: GrantFiled: December 27, 2001Date of Patent: July 17, 2007Inventors: Margarete Focke, Vera Mahler, Wolfgang R. Sperr, Peter Valent, Dietrich Kraft, Rudolf Valenta
-
Patent number: 7148019Abstract: A recombinant DNA molecule comprising a nucleotide sequence (I) which codes for a polypeptide displaying the antigenicity of one, two or more of the Phl p I epitope clones (28, 34, 41, 42, 43, 45, 50, 52, 64, 80, 85, 86, 95, 97, 98, 103, 108, 109, 113, 114), with the amino acid sequences defined in SEQ ID NOS: 5, 7, 9 and 12–28, and preferably being derived from grasses or monocotyledonic plants, or a nucleotide sequence (II) which hybridizes with such a nucleotide sequence (I) under conditions of high, stringency. Polypeptides displaying the antigenicity of one, two or more of the Phl p I epitope clones (28, 34, 41, 42, 43, 50, 52, 64, 80, 85, 86, 95, 97, 98, 103, 108, 109, 113, 114). Recombinant expression vectors containing the recombinant molecule and host cells transformed with the vector. Diagnostic methods based on utilizing the polypeptides in immunoassays for humoral antibodies and cellular reactions.Type: GrantFiled: June 5, 2002Date of Patent: December 12, 2006Assignee: Phadia ABInventors: Tanja Ball, Susanne Vrtala, Wolfgang Sperr, Peter Valent, Markus Susani, Dietrich Kraft, Rudolf Valenta, Sylvia Laffer
-
Publication number: 20060263391Abstract: A process for the preparation of an hypoallergenic mosaic antigen derived from an allergen is disclosed whereby a) in a first step the allergen is split into at least two parts and the IgE reactivity of each part is determined and b) in a second step those parts of the allergen which have no detectable IgE reaction are combined to a mosaic antigen which comprises the amino acids of the allergen but the order of the amino acids of the mosaic antigen is different from that of the naturally occurring allergen.Type: ApplicationFiled: December 18, 2003Publication date: November 23, 2006Inventors: Nadine Mothes, Sabine Stumvoll, Margit Focke, Birgit Linhart, Maria-Theresa Krauth, Peter Valent, Dietrich Kraft, Rudolf Valenta
-
Publication number: 20060216314Abstract: The present invention pertains to polypeptides derived from the timothy grass pollen allergen Phi p 7. The polypeptides display reduced allergen activity and are useful as allergy vaccines for treatment of sensitized allergic patients and for prophylactic vaccination.Type: ApplicationFiled: September 25, 2003Publication date: September 28, 2006Applicant: BIOMAY PRODUKTIONS- UND HANDELS-AKTIENGESELLSCHAFTInventors: Kerstin Westritschnig, Margarete Focke, Anna Twardosz, Peter Valent, Petra Verdino, Walter Keller, Dietrich Kraft, Rudolf Valenta
-
Patent number: 7108858Abstract: The present invention is drawn to an immunogen derived from a protein allergen, which is a) a non-anaphylactic immunogenic recombinant fragment of the protein allergen which contains an IgG epitope partly but not wholly overlapping an IgE epitope of the protein allergen; b) a polymeric form of the fragment, in which the fragment constitutes the monomeric units; or c) a non-anaphylactic recombinant polymeric form of the protein allergen having 2–10 monomeric units, in which the protein allergen constitutes the monomeric units. The present invention is further drawn to the use of the immunogen for in vitro diagnoses of type I allergy and hyposensitization.Type: GrantFiled: July 3, 2001Date of Patent: September 19, 2006Assignee: Pharmacia Diagnostics ABInventors: Rudolf Valenta, Susanne Vrtala, Luca Vangelista, Hans-Georg Eichler, Wolfgang R. Sperr, Peter Valent, Christof Ebner, Dietrich Kraft, Hans Grönlund
-
Publication number: 20060140969Abstract: The present invention relates to non-naturally occurring polypeptides derived from fish allergens such as parvalbumin Cyp c 1.01 from carp. The polypeptides display reduced allergenic activity and are useful as allergy vaccines for treatment of sensitized allergic patients and for prophylactic vaccination.Type: ApplicationFiled: August 24, 2004Publication date: June 29, 2006Applicant: BIOMAY Produktions-und Handels-AktiengesellschaftInventors: Rudolf Valenta, Peter Valent, Susanne Spitzauer, Ines Swoboda